Table 1 List of MSC Exo clinical trials recorded up to September 2021 (available on https://clinicaltrials.gov/ct2/home)
From: Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine
Status | Study | Conditions | Source | Interventions | Phase |
|---|---|---|---|---|---|
Not yet recruiting | Nebulization of MSC Exo in patients with acute respiratory distress syndrome | Acute respiratory distress syndrome | Allogenic MSCs | Low/medium/and high doses of MSC Exo | I and II |
Completed | Aerosol inhalation of MSC Exo in healthy volunteers | Healthy | Allogenic adipose MSCs | 1X to 8X concentration of Exo | I |
Recruiting | Effect of umbilical MSCs Exo on dry eye in patients with cGVHD | Dry eye | Umbilical MSCs | 10ug exosomal protein/drop | I and II |
Completed | Inhalation of MSC Exo in severe Coronavirus pneumonia | Coronavirus | Allogenic adipose MSCs | 2.0 × 108 nanovesicles/3 ml | I |
Recruiting | Allogenic MSC Exo in patients with acute ischemic stroke | Cerebrovascular disorders | Allogenic MSCs | Exo enriched by miR-124 | I and II |
Not yet recruiting | MSC Exo for multiple organ dysfunction syndromes after surgical repair of acute type A aortic dissection | Multiple organ failure | Umbilical MSCs | Intravenous administration of Exo (150 mg) | Not applicable |
Recruiting | MSC Exo nebulization for the treatment of pulmonary infection | Drug-resistant | Allogenic adipose MSCs | 8.0 × 108 nanovesicles/3 ml | I and II |
Active, not recruiting | MSC Exo for macular holes | Macular holes | Umbilical MSCs | Intraviterous injection of 20–50 μg/10 μl PBS | I |
Not yet recruiting | MSC Exo for the treatment of acute respiratory distress syndrome (COVID-19) | COVID-19 | Perinatal MSC Exo | Intravenous administration of MSC Exo | I and II |
Not yet recruiting | MSC Exo on the therapy for intensively Ill children | Sepsis and critical illness | MSC Exo | ND | ND |
Recruiting | MSC Exo in patients with Alzheimer's disease | Alzheimer Disease | Allogenic adipose MSCs | The nasal drip of low/medium and high doses of MSC Exo | I and II |
Unknown | MSC Exo for induction of beta-cell mass in type I diabetes mellitus | Diabetes mellitus type 1 | Cord blood MSC Exo | Intravenous injection | II and III |
Enrolling by invitation | MSC Exo inhalation in COVID-19 associated pneumonia | SARS-CoV-2 pneumonia | MSC Exo | Inhalation of 0.5–2 × 1010 nanoparticles | II |
Completed | MSC Exo inhalation in COVID-19 associated pneumonia | SARS-CoV-2 pneumonia | MSC Exo | Inhalation of 0.5–2 × 1010 nanoparticles | I and II |
Not yet recruiting | MSC Exo for dystrophic epidermolysis bullosa | Dystrophic epidermolysis bullosa | Allogeneic bone marrow MSC Exo | Topical administration | I and II |
Completed | MSC EVs inhalation in COVID-19 associated pneumonia | Covid19 | Bone marrow MSC Exo | Intravenous | II |
Not yet recruiting | MSC CM on enhancers of bone formation in bone grafting | Bone loss, osteoclastic | Autologous adipose MSC CM | Injection to the maxillary sinuses | I |